These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34799696)

  • 1. COVID-19 vaccination and cancer immunotherapy: should they stick together?
    Brest P; Mograbi B; Hofman P; Milano G
    Br J Cancer; 2022 Jan; 126(1):1-3. PubMed ID: 34799696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.
    Malek AE; Cornejo PP; Daoud N; Alam M
    Immunotherapy; 2022 Feb; 14(2):91-94. PubMed ID: 34747190
    [No Abstract]   [Full Text] [Related]  

  • 3. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
    Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
    Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.
    Chen YW; Tucker MD; Beckermann KE; Iams WT; Rini BI; Johnson DB
    Eur J Cancer; 2021 Sep; 155():291-293. PubMed ID: 34400057
    [No Abstract]   [Full Text] [Related]  

  • 5. Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.
    Abid MB
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 Updates: Pfizer-BioNTech COVID-19 vaccine.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35134045
    [No Abstract]   [Full Text] [Related]  

  • 7. Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment.
    Buttiron Webber T; Provinciali N; Musso M; Ugolini M; Boitano M; Clavarezza M; D'Amico M; Defferrari C; Gozza A; Briata IM; Magnani M; Paciolla F; Menghini N; Marcenaro E; De Palma R; Sacchi N; Innocenti L; Siri G; D'Ecclesiis O; Cevasco I; Gandini S; DeCensi A
    Eur J Cancer; 2021 Dec; 159():105-112. PubMed ID: 34742157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe cutaneous adverse reaction following COVID-19 vaccination and immunotherapy: a second hit?
    Hussain K; Kawsar A; Weir J; Au L; Turajlic S; Larkin J; Fearfield L
    Clin Exp Dermatol; 2022 Jan; 47(1):149-151. PubMed ID: 34260095
    [No Abstract]   [Full Text] [Related]  

  • 9. In brief: Pfizer/BioNTech COVID-19 vaccine authorized for children 5-11 years old.
    Med Lett Drugs Ther; 2021 Nov; 63(1638):185. PubMed ID: 35085214
    [No Abstract]   [Full Text] [Related]  

  • 10. Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2.
    Kayukawa S; Nanya K; Morita M; Ina K; Ota Y; Hasegawa S
    Microbiol Spectr; 2021 Dec; 9(3):e0103621. PubMed ID: 34756062
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer.
    Debie Y; Vandamme T; Goossens ME; van Dam PA; Peeters M
    Eur J Cancer; 2022 Mar; 163():177-179. PubMed ID: 35077960
    [No Abstract]   [Full Text] [Related]  

  • 12. Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up.
    Lasagna A; Lilleri D; Agustoni F; Percivalle E; Borgetto S; Alessio N; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Secondino S; Falzoni M; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Feb; 7(1):100359. PubMed ID: 34973510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience.
    Gilboa M; Mandelboim M; Indenbaum V; Lustig Y; Cohen C; Rahav G; Asraf K; Amit S; Jaber H; Nemet I; Kliker L; Bar-Haim E; Mendelson E; Doolman R; Rubin C; Regev-Yochay G; Kreiss Y
    J Infect Dis; 2022 Mar; 225(5):785-792. PubMed ID: 34850049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis.
    Saadeldin MK; Abdel-Aziz AK; Abdellatif A
    Med Hypotheses; 2021 Jan; 146():110365. PubMed ID: 33221134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-related adverse events: what we've learned and where we're heading.
    Badran YR; Leet DE; Dougan M
    Expert Rev Anticancer Ther; 2020 Sep; 20(9):727-730. PubMed ID: 32726153
    [No Abstract]   [Full Text] [Related]  

  • 16. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
    Nemet I; Kliker L; Lustig Y; Zuckerman N; Erster O; Cohen C; Kreiss Y; Alroy-Preis S; Regev-Yochay G; Mendelson E; Mandelboim M
    N Engl J Med; 2022 Feb; 386(5):492-494. PubMed ID: 34965337
    [No Abstract]   [Full Text] [Related]  

  • 17. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma.
    Avivi I; Balaban R; Shragai T; Sheffer G; Morales M; Aharon A; Lowenton-Spier N; Trestman S; Perry C; Benyamini N; Mittelman M; Tabib Y; Bar Lev T; Zavaro M; Herishanu Y; Luttwak E; Cohen YC
    Br J Haematol; 2021 Oct; 195(2):186-193. PubMed ID: 34196388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
    Shaw RH; Stuart A; Greenland M; Liu X; Nguyen Van-Tam JS; Snape MD;
    Lancet; 2021 May; 397(10289):2043-2046. PubMed ID: 33991480
    [No Abstract]   [Full Text] [Related]  

  • 19. Do health-care workers need a COVID-19 vaccine booster?
    Cirillo N
    Lancet Infect Dis; 2022 Jan; 22(1):20. PubMed ID: 34953546
    [No Abstract]   [Full Text] [Related]  

  • 20. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors.
    Waissengrin B; Agbarya A; Safadi E; Padova H; Wolf I
    Lancet Oncol; 2021 May; 22(5):581-583. PubMed ID: 33812495
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.